Compass Planning Associates Inc Acquires 5,623 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Compass Planning Associates Inc grew its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 91.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,776 shares of the medical instruments supplier's stock after purchasing an additional 5,623 shares during the quarter. LeMaitre Vascular comprises about 1.0% of Compass Planning Associates Inc's holdings, making the stock its 11th biggest holding. Compass Planning Associates Inc owned about 0.05% of LeMaitre Vascular worth $988,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Raymond James Financial Inc. bought a new position in LeMaitre Vascular in the fourth quarter worth $14,900,000. Rockefeller Capital Management L.P. purchased a new stake in shares of LeMaitre Vascular in the 4th quarter worth about $7,787,000. Segall Bryant & Hamill LLC bought a new position in shares of LeMaitre Vascular in the 4th quarter worth about $5,446,000. Invesco Ltd. increased its stake in shares of LeMaitre Vascular by 50.5% in the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after acquiring an additional 58,720 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in LeMaitre Vascular by 7,486.5% during the 1st quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock valued at $4,519,000 after acquiring an additional 53,154 shares during the period. 84.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO George W. Lemaitre sold 18,733 shares of the company's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the completion of the sale, the chief executive officer now owns 1,873,651 shares in the company, valued at approximately $158,829,395.27. This represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 100,000 shares of company stock valued at $8,556,857 over the last three months. Insiders own 9.50% of the company's stock.

Analyst Ratings Changes

A number of brokerages have weighed in on LMAT. Oppenheimer cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital upped their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Wells Fargo & Company assumed coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $97.83.

LeMaitre Vascular Trading Down 0.6%

LMAT stock traded down $0.49 during midday trading on Wednesday, hitting $83.14. The company's stock had a trading volume of 146,477 shares, compared to its average volume of 168,293. The firm's 50-day moving average is $83.68 and its 200-day moving average is $90.69. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The company has a market cap of $1.88 billion, a PE ratio of 45.43, a P/E/G ratio of 2.22 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $59.87 million for the quarter, compared to the consensus estimate of $57.61 million. During the same period in the previous year, the company earned $0.44 earnings per share. The company's revenue for the quarter was up 12.0% compared to the same quarter last year. Analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.96%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.